https://www.europesays.com/dk/189995/ GLP-1 boom fuels supplement sales and calls for oversight #collagen #ConsumerSafety #DietarySupplements #FDA #FiberSupplements #GLP1Drugs #healthcare #NovoNordisk #ObesityTreatment #ozempic #SocialMediaInfluencers #SupplementRegulation #SupplementSales #TikTokShop #vitamins #Wegovy #WeightLossDrugs
#obesitytreatment — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #obesitytreatment, aggregated by home.social.
-
https://www.europesays.com/ie/742793/ GLP-1 Drugs and Mental Health: Effects on Depression and Anxiety #AddictionResearch #BingeEatingDisorder #BrainHealth #DepressionResearch #DrugSafety #Éire #glp1 #Health #IE #Ireland #MentalHealth #ObesityTreatment #Psychiatry #semaglutide
-
GLP-1 Drugs and Obstructive Sleep Apnea: How Weight Loss Medications Improve Breathing During Sleep
IntroductionClinical trial evidenceFDA approval and regulatory developmentsCardiometabolic and secondary benefitsFuture directionsReferences What can treatments targetin…
#NewsBeep #News #Health #AU #Australia #CardiometabolicHealth #glp1 #liraglutide #obesitytreatment #Obstructivesleepapnea #SleepApnea #sleephealth #SleepResearch #Tirzepatide #weightmanagement
https://www.newsbeep.com/au/933415/ -
https://www.europesays.com/africa/478094/ Unapproved obesity treatment sold by influencers raises alarm in South Africa #BorderManagementAuthority #EliLilly #MichaelMasiapato #ObesityTreatment #PharmaceuticalTaskGroup #ptg #retatrutide #SouthAfrica #SouthAfricanHealthProductsRegulatoryAuthority #SouthAfricanPharmacyCouncil #StavrosNicolaou #VincentTlala
-
Samsung Biologics Secures 87.9% of PolyPeptide in Tender Offer, Deal to Close by End of November — BigGo Finance
Samsung Biologics (207940.KS) has secured 87.88% of the shares targeted in its tender offer for PolyPeptide Group, a…
#EuropeSays #Korea #KR #SamsungBiologics #CDMO #DraupnirHolding #MorganStanley #obesitytreatment #peptide #PolyPeptideGroup #Samsung #SamsungPeptide
https://www.europesays.com/korea/186662/ -
https://www.europesays.com/dk/183701/ Hengrui and Novo Nordisk in USD2.6bn drug licensing deal | China #China #DrugDevelopment #HengruiPharmaceuticals #IntellectualProperty #LifeSciences #NovoNordisk #ObesityTreatment #OutLicensing #PharmaceuticalIndustry #Pharmaceuticals #Ropes&Gray #SidleyAustin
-
https://www.europesays.com/dk/177553/ Novo Nordisk Reports Wegovy Liver Fat Reduction Analysis #DiabetesResearch #ESSENCETrial #FattyLiverDisease #LiverFatReduction #MASH #NovoNordisk #NVOStock #ObesityTreatment #semaglutide #STEPUPTrial #Wegovy
-
DATE: September 30, 2026 at 09:00AM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: Weight-loss drug semaglutide alters reward-seeking behavior in healthy mice
URL: https://www.psypost.org/weight-loss-drug-semaglutide-alters-reward-seeking-behavior-in-healthy-mice/
A new small study in healthy mice reveals that the popular weight-loss drug semaglutide alters behavior and brain activity related to reward and stress. Researchers found that daily doses of the drug changed how animals pursued natural rewards and reacted to stressful situations, while also shifting electrical patterns in a central reward circuit. The findings were published in the journal Molecular Brain.
Semaglutide is a medication widely used to treat diabetes and obesity. The medication is frequently recognized by brand names such as Ozempic and Wegovy. It mimics a naturally occurring hormone called GLP-1, which regulates appetite and blood sugar. Recently, scientists have begun exploring whether the drug might also treat addiction by dampening the brain’s response to cravings.
Most prior research has focused on animal models with obesity or diabetes. To understand the drug’s baseline effects on a typical nervous system, researchers Alejo Mosqueira, Sanaz Ansarifar, and their colleagues at Aarhus University investigated how semaglutide impacts the behavior and brain waves of healthy mice. The research team specifically looked at the nucleus accumbens, a region deep in the brain that plays a primary role in processing motivation, pleasure, and reward.
The researchers first designed a behavioral experiment using healthy adult male mice. They divided the animals into two main treatment groups to test different dosing schedules. One group received a weekly injection of semaglutide for eight weeks, which mirrors how the drug is prescribed to human patients. The second group received daily injections to account for the faster metabolism of mice and to observe any short-term behavioral changes.
Following the injection periods, the researchers ran the mice through a battery of tests designed to measure movement, anxiety, and reward-seeking habits. They monitored the animals’ food intake, water consumption, and body weight throughout the process to track general physiological health. Both the daily and weekly groups experienced substantial weight loss, alongside noticeable reductions in eating and drinking. The researchers ran statistical analyses to confirm that the weight loss itself was not responsible for the altered behavior.
When assessing behavior, the researchers found changes exclusively in the daily injection group. In an open field test used to measure general movement and anxiety, the daily-dosed mice displayed an increase in jumping against the walls of the testing box. The researchers interpret this as an increased attempt to escape the enclosure. In a separate marble burying test used to measure repetitive actions, the differences between the treated and untreated mice were not statistically significant.
The team also used a nestlet shredding test, providing the mice with a cotton nesting material to see how much they would tear it apart. Mice given daily semaglutide shredded far less of the material than the control group. This reduction suggests a shift in how the animals explore their environment or a potential increase in underlying anxiety.
To evaluate reward-seeking behavior without relying on food, the researchers used a scent-based test. Healthy male mice naturally seek out the smell of female mouse urine, which acts as a rewarding social cue. The semaglutide-treated mice spent much less time sniffing the female urine than the untreated mice. This drop in interest indicates a suppression of natural reward-seeking drives.
Finally, the researchers placed the mice in small containers of water for a forced swimming test, which is commonly used to measure stress coping and depressive-like states. Mice treated with daily semaglutide spent less time floating motionless and more time actively swimming compared to the control group. This behavior often suggests improved stress resilience or an antidepressant-like effect.
In a separate experiment, Mosqueira and Ansarifar’s team examined how a single dose of semaglutide affects neural activity. They anesthetized a small group of healthy mice and inserted microscopic electrodes into the nucleus accumbens. The researchers recorded the animals’ baseline brain waves for 30 minutes, injected the drug, and then recorded for another hour.
The researchers focused on local field potentials, which are the collective electrical signals generated by large groups of neurons firing together. They analyzed different speeds of brain waves, breaking the signals down into slower rhythms known as delta, theta, and alpha waves. These specific wave patterns are heavily involved in how the brain anticipates and responds to rewards, making them a useful target for understanding motivation.
Following the semaglutide injection, the rhythmic electrical activity in the nucleus accumbens shifted. The dominant frequencies of the delta, theta, and alpha waves became slightly faster. At the same time, the physical strength or amplitude of these slow waves decreased. The researchers note that a reduction in delta and theta wave strength aligns with a dampened reward anticipation system.
The study relies on a relatively small number of animals, and the behavioral changes only appeared under the daily dosing schedule. The weekly injection group lost weight but did not exhibit the same behavioral shifts. This discrepancy suggests that the frequency of the dose heavily influences the behavioral outcomes in healthy animals.
The brain wave recordings took place while the mice were under anesthesia, which fundamentally alters normal electrical activity in the brain. The behavioral tests, conversely, involved awake animals taking the drug over multiple days. Because of these differing conditions, the electrical changes cannot be directly linked to the behavioral shifts.
Future research will need to record brain activity in awake, freely moving animals over longer periods. Measuring these electrical signals while mice are actively making choices could clarify exactly how semaglutide changes motivation. Testing different dosages may also help determine whether these effects apply broadly across different treatment regimens.
The study, “Semaglutide alters behaviour and nucleus accumbens oscillatory activity in healthy mice,” was authored by Alejo Mosqueira, Sanaz Ansarifar, Sadegh Nabavi, and Andrea Moreno.
URL: https://www.psypost.org/weight-loss-drug-semaglutide-alters-reward-seeking-behavior-in-healthy-mice/
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #Semaglutide #WeightLossDrug #NucleusAccumbens #RewardSeeking #BrainOscillations #GLP1 #MiceStudy # addons: Avoid "add-ons" — just hashtags. #OpenFieldTest #StressResilience #Dopamine #BehavioralScience #Nutrition #ObesityTreatment #Ozempic Wegovy
-
Obesity costs Europe billions and claims 278,000 lives a year, study finds
Every year, obesity and obesity-linked diseases cause 278,000 deaths and the loss of almost 8 million years of healthy…
#Europe #EU #EFPIAobesitystudy #elevatedBMI #EUSafeHeartsPlan #GLP-1drugs #obesitycostsEurope #obesitydeathsEurope #obesityeconomicburden #obesityEurope #obesityprevention #obesitytreatment #OfficeofHealthEconomics #overweightEurope
https://www.europesays.com/europe/148601/ -
https://www.europesays.com/dk/176118/ LLY Vs NVO: Foundayo Beats Novo’s Oral Semaglutide On Weight Loss, Blood Sugar In New Finding #BloodSugarLevels #BodyWeight #EliLilly #EuropeanAssociationForTheStudyOfDiabetes #NovoNordisk #ObesityTreatment #semaglutide #WeightLoss #WeightLossDrug
-
Obesity costs Europe billions and 278,000 lives a year
Every year, obesity and obesity-linked diseases cause 278,000 deaths and the loss of almost 8 million years of healthy…
#Europe #EU #EFPIAobesitystudy #elevatedBMI #EUSafeHeartsPlan #GLP-1drugs #obesitycostsEurope #obesitydeathsEurope #obesityeconomicburden #obesityEurope #obesityprevention #obesitytreatment #OfficeofHealthEconomics #overweightEurope
https://www.europesays.com/europe/148516/ -
https://www.europesays.com/ch/134591/ Roche Obesity Drug Enicepatide Delivers 15.5% Weight Loss in Phase 2 Diabetes Trial #DiabetesManagement #HbA1cLevels #NovoNordisk #ObesityTreatment #patients #Roche #Type2Diabetes #WeightManagement
-
https://www.europesays.com/dk/171133/ Novo Nordisk reports CagriSema phase 3 weight loss results #cagrisema #DiabetesMedicine #GLP1Drugs #NovoNordisk #NovoNordiskNVOStock #ObesityTreatment #PharmaceuticalStocks #REDEFINE9 #REIMAGINE5 #WeightLossDrugs
-
https://www.europesays.com/uk/1204973/ Bangkok Post – Weight-loss injection pens now require a doctor’s prescription #DiabetesMedication #FdaThailand #GLP1ReceptorAgonists #Health #Medication #ObesityTreatment #PrescriptionMedication #PublicHealthSafety #SemaglutideRegulation #UK #UnitedKingdom #WeightLossPens
-
Bangkok Post – Weight-loss injection pens now require a doctor’s prescription
PUBLISHED : 14 Sep 2026 at 15:34 Weight-loss injection pens seized from an online seller’s house in Nonthaburi…
#NewsBeep #News #Medication #diabetesmedication #fdathailand #GLP-1receptoragonists #Health #Obesitytreatment #prescriptionmedication #publichealthsafety #semaglutideregulation #UK #UnitedKingdom #weight-losspens
https://www.newsbeep.com/uk/770962/ -
Bangkok Post – Weight-loss injection pens now require a doctor’s prescription
PUBLISHED : 14 Sep 2026 at 15:34 Weight-loss injection pens seized from an online seller’s house in Nonthaburi…
#NewsBeep #News #Medication #CA #Canada #diabetesmedication #fdathailand #GLP-1receptoragonists #Health #obesitytreatment #prescriptionmedication #publichealthsafety #semaglutideregulation #weight-losspens
https://www.newsbeep.com/ca/895909/ -
https://www.europesays.com/ie/688149/ Bangkok Post – Weight-loss injection pens now require a doctor’s prescription #DiabetesMedication #Éire #FdaThailand #GLP1ReceptorAgonists #Health #IE #Ireland #Medication #ObesityTreatment #PrescriptionMedication #PublicHealthSafety #SemaglutideRegulation #WeightLossPens
-
https://www.europesays.com/dk/161253/ Novo Nordisk reports semaglutide child obesity trial data #ChildhoodObesity #ClinicalTrial #GLP1Medicine #HealthcareStocks #NovoNordisk #NYSENVO #ObesityTreatment #semaglutide #STEPYoungTrial
-
Combination therapies for obesity show promising results in clinical trials
📰 Original title: The hallmarks of skeletal muscle health | Nature Metabolism
🤖 IA: It's not clickbait ✅
👥 Users: It's not clickbait ✅View full AI summary https://en.killbait.com/combination-therapies-for-obesity-show-promising-results-in-clinical-trials.html?utm_source=mastodon_social&utm_medium=social&utm_campaign=killbait.mastodon_social
#health #obesitytreatment #metabolictherapies #pharmaceuticals
-
https://www.europesays.com/ie/636394/ GLP-1 Drugs Have Been Linked to More Than 200 Reported Deaths in the UK Alone #diabetes #Éire #GLP1 #Health #IE #Ireland #liraglutide #Medication #ObesityTreatment #ozempic #semaglutide #SideEffects #tirzepatide #Wegovy #WeightLossDrugs
-
Oral GLP-1 Drug Shows Significant Weight Loss in 36-Week Trial
📰 Original title: New GLP-1 pill delivers up to 12% weight loss in 36 weeks
🤖 IA: It's clickbait ⚠️
👥 Users: It's clickbait ⚠️View full AI summary https://en.killbait.com/oral-glp-1-drug-shows-significant-weight-loss-in-36-week-trial.html?utm_source=mastodon_social&utm_medium=social&utm_campaign=killbait.mastodon_social
-
https://www.europesays.com/uk/1134711/ Serena Williams Defends GLP-1 Weight-Loss Drug Use: What Doctors Want You To Know #AntiObesity #AntiObesityDrugsStigma #BariatricSurgery #ChronicDiseaseAndExercise #GLPDrugs #GLP1WeightLossMedication #Health #MedicalEvaluationForObesity #Medication #ObesityAndDementiaRisk #ObesityAsChronicDisease #ObesityTreatment #Semaglutide #SemaglutideAdverseEffects #SerenaWilliams #UK #UnitedKingdom #WeightManagement #ZepboundTirzepatide
-
Serena Williams Defends GLP-1 Weight-Loss Drug Use: What Doctors Want You To Know
Tennis legend Serena…
#NewsBeep #News #Medication #antiobesity #antiobesitydrugsstigma #AU #Australia #BariatricSurgery #chronicdiseaseandexercise #GLPdrugs #GLP1weightlossmedication #Health #medicalevaluationforobesity #obesityanddementiarisk #obesityaschronicdisease #obesitytreatment #semaglutide #SemaglutideAdverseEffects #SerenaWilliams #weightmanagement #Zepboundtirzepatide
https://www.newsbeep.com/au/845978/ -
Serena Williams Defends GLP-1 Weight-Loss Drug Use: What Doctors Want You To Know
Tennis legend Se…
#NewsBeep #News #Medication #antiobesity #antiobesitydrugsstigma #bariatricsurgery #chronicdiseaseandexercise #GLPdrugs #GLP1weightlossmedication #Health #medicalevaluationforobesity #obesityanddementiarisk #obesityaschronicdisease #Obesitytreatment #Semaglutide #SemaglutideAdverseEffects #SerenaWilliams #UK #UnitedKingdom #weightmanagement #Zepboundtirzepatide
https://www.newsbeep.com/uk/729664/ -
Discover the key differences between Semaglutide and Tirzepatide for weight loss. Learn how they work, compare effectiveness, side effects, dosing and safety data to make an informed choice for your health journey.
#Semaglutide #Tirzepatide #WeightLoss #ObesityTreatment #HealthyLiving
https://www.scientificworldinfo.com/2026/08/difference-between-semaglutide-and-tirzepatide-for-weight-loss.html -
https://www.europesays.com/ie/623783/ Serena Williams Defends GLP-1 Weight-Loss Drug Use: What Doctors Want You To Know #AntiObesity #AntiObesityDrugsStigma #BariatricSurgery #ChronicDiseaseAndExercise #Éire #GLPDrugs #GLP1WeightLossMedication #Health #IE #Ireland #MedicalEvaluationForObesity #Medication #ObesityAndDementiaRisk #ObesityAsChronicDisease #ObesityTreatment #semaglutide #SemaglutideAdverseEffects #SerenaWilliams #WeightManagement #ZepboundTirzepatide
-
https://www.europesays.com/dk/140943/ Novo Nordisk shares fall despite improved outlook as Wegovy sales disappoint #DanishKroner #NovoNordisk #ObesityTreatment #ObesityTreatments #WeightLoss
-
https://www.europesays.com/dk/138270/ Sublingual semaglutide offered to UK practices despite Novo Nordisk concerns #compounding #NovoNordisk #ObesityTreatment #patients #PCCA #PharmaceuticalTechnology #ProfessionalCompoundingCentersOfAmerica #SafetyConcerns #semaglutide #UK #WeightLossDrugs
-
https://www.europesays.com/dk/135781/ Novo Nordisk seeks orders to block Eli Lilly weight-loss drug ads | World News #DiabetesDrugs #DrugAdvertising #DrugMarketing #EliLilly #GLP1Drugs #HealthcareNews #MisleadingAds #Mounjaro #NovoNordisk #ObesityDrugs #ObesityTreatment #ozempic #PharmaceuticalIndustry #PreliminaryInjunction #USCourt #USLawsuit #Wegovy #WeightLossDrugs #WeightLossMarket #zepbound
-
https://www.europesays.com/dk/134958/ Novo Nordisk takes action to stop multiple misleading #CopenhagenStockExchange:NOVOB #EliLilly #FalseAdvertsingLawsuit #GLP1 #LanhamAct #Mounjaro #NovoNordisk #NovoNordiskA/S #ObesityTreatment #ozempic #Type2 #Wegovy #zepbound
-
https://www.europesays.com/dk/134838/ Novo Nordisk seeks court order to halt Eli Lilly weight-loss drug advertisements #Advertisements #DiabetesDrug #EliLilly #LegalDispute #MedicalResearcher #NovoNordisk #ObesityTreatment #PharmaceuticalCompanies #PreliminaryInjunction
-
https://www.europesays.com/dk/133815/ Novo Nordisk Sues Eli Lilly Over Wegovy and Mounjaro Obesity Drug Ads #Mounjaro #NovoNordisk #ObesityDrug #ObesityTreatment #Wegovy #마운자로 #비만약 #비만치료제 #위고비
-
https://www.europesays.com/ch/106658/ Samsung Biologics Acquires Swiss CDMO for approximately $1.8 Billion, Making a Major Push into the Obesity Drug Market — BigGo Finance #CDMO #EliLilly #GLP1 #JohnRim #KiwoomSecurities #mounjaro #NHInvestment&Securities #NovoNordisk #ObesityTreatment #Peptide #PolyPeptideGroup #SamsungBiologics #Swiss #Switzerland #Wegovy
-
Samsung Biologics Acquires Swiss CDMO for approximately $1.8 Billion, Making a Major Push into the Obesity Drug Market — BigGo Finance
Samsung Biologics (207940) is investing approximately 2.7 trillion won (approximately $1.8 billion) to acquire PolyPeptide Group, a global…
#EuropeSays #Korea #KR #SamsungBiologics #CDMO #EliLilly #GLP-1 #JohnRim #KiwoomSecurities #Mounjaro #NHInvestment&Securities #NovoNordisk #obesitytreatment #peptide #PolyPeptideGroup #Samsung #Wegovy
https://www.europesays.com/korea/94800/ -
Samsung Biologics Acquires PolyPeptide for 2.7 Trillion Won, Expanding Growth Axis Beyond Antibodies
PolyPeptide Group’s India (Ambernath) plant. Photo courtesy of Samsung Biologics Samsung Biologics’ (207940.KS) acquisition of Swiss peptide contract…
#EuropeSays #Korea #KR #SamsungBiologics #biopharmaceuticalM&A #GLP-1 #Koreabiotech #NHInvestment&Securities #obesitytreatment #PeptideCDMO #PolyPeptide #Samsung
https://www.europesays.com/korea/92946/ -
The obesity treatment landscape is changing fast, with GLP-1 drugs opening the door to more effective care than ever before. #glp1drugs #obesitytreatment #medicalresearch
Posted into FLIPBOARD EXCHANGE FEED 🗞️ @flipboard-exchange-feed-Econopass
-
Pfizer’s experimental obesity drug Berobenatide could become the world’s first once-a-month GLP-1 injection https://english.mathrubhumi.com/lifestyle/health/pfizer-berobenatide-monthly-glp1-weight-loss-drug-piti6hxh?utm_source=dlvr.it&utm_medium=mastodon #Berobenatide #Pfizer #WeightLoss #ObesityTreatment #GLP1
-
A Sympathetic Treatment for Obesity
•🧠 Introduction of PEGyAMPH, a new non-CNS penetrative compound
•👔 Maintains normothermia and spares cardiovascular side effects
•⚖️ Promotes lipolysis and thermogenesis without affecting food intake#AMPhDerivatives #ObesityTreatment #CellMetabolism https://dev.tnyp.me/qi70nPHW/m
-
Obese Seek Weight Loss Drugs Amidst Shifting Insurance Tides
Insurance like Medicare and Medicaid are limiting coverage for weight loss drugs (Wegovy, Ozempic). Many obese patients now face higher costs or denied access.
#WeightLossDrugs, #Ozempic, #Wegovy, #InsuranceCoverage, #ObesityTreatment
https://newsletter.tf/weight-loss-drug-coverage-changes-obese-2026/
-
Insurance coverage for popular weight loss drugs like Wegovy and Ozempic is becoming harder to get. This is different from last year when more people could access them for obesity.
#WeightLossDrugs, #Ozempic, #Wegovy, #InsuranceCoverage, #ObesityTreatment
https://newsletter.tf/weight-loss-drug-coverage-changes-obese-2026/ -
Obesity Treatment Through Naturopathy in Raipur, Chhattisgarh | Five Lotus Indo German
https://fivelotusindogerman.com/obesity-treatment/
#ObesityTreatment #NaturopathyCare #NaturalWeightLoss #HolisticHealing #RaipurWellness #WeightLossJourney #FiveLotusIndoGerman #HealthyLiving #NaturopathyIndia
-
Scientists find brain cells that cause weight loss—without nausea. This could lead to safer, smarter obesity drugs. #BrainScience #ObesityTreatment #Semaglutide
https://geekoo.news/the-brain-cells-that-control-weight-loss-without-side-effects/
-
The Trump administration's latest move sparks controversy! The decision to oppose a Biden proposal for Medicare coverage of obesity medications signals a major policy shift that could limit access for beneficiaries. This development not only affects treatment options but also raises concerns over health outcomes for those facing obesity. Discover the implications of this political clash in healthcare and its effects. Read more here: https://finance.yahoo.com/video/trump-admin-reportedly-drop-medicare-211717981.html #HealthcarePolicy #Medicare #ObesityTreatment #TrumpAdministration #BidenAdministration
Kudos to the writer for shedding light on this critical issue!
-
🌍💊 Novo Nordisk's weight-loss drug Wegovy sees a massive 57% sales increase, doubling patient numbers to 2.2 million worldwide! The company anticipates up to 24% growth in 2025.
https://www.pharmacy.biz/news/novo-nordisk-sees-strong-surge-in-wegovy-sales/More details here: pharmacy.biz 🏥 #Healthcare #ObesityTreatment #NovoNordisk
-
The Dark Side of Weight Loss: GLP-1 RAs Linked to Increased Psychiatric Risks
A groundbreaking study reveals a startling correlation between glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications and heightened risks of depression, anxiety, and suicidal behavior in pat...
-
Mounjaro will soon be available as a weight loss treatment on the NHS – here’s what that means for patients
#Health #Mounjaro #Ozempic #Wegovy #WeightLossDrugs #Tirzepatide #WeightLoss #NHS #ObesityTreatment #HealthCare #ObesityCrisis #PatientCare
https://the-14.com/mounjaro-will-soon-be-available-as-a-weight-loss-treatment-on-the-nhs-heres-what-that-means-for-patients/ -
🧵2/6 These drugs are not just making headlines; they're making a significant impact, helping individuals lose up to 20% of their body weight on average. This breakthrough comes at a time when the need has never been greater. #ObesityTreatment #MedicalBreakthrough
-
Unlocking the power of bariatric surgery in the fight against obesity
Maria Iliakova is a bariatric and general surgeon.
https://youtube.com/shorts/V78qfm1rAJo
Listen here: https://kevinmd.com/podcast
#BariatricSurgery #ObesityTreatment #HealthcareApproach #CompassionateCare #MentalWellBeing #HolisticHealth #NoBlame #MedicalOptions #SurgicalInterventions
-
Effective obesity solutions beyond the norm: Genetics matter
Franchell Hamilton is a bariatric surgeon.
https://youtube.com/shorts/t1tdFeCNhxM
Listen here: https://kevinmd.com/podcast
#Healthcare #ObesityTreatment #GeneticFactors #PatientSupport #MedicalApproach #WeightStigma #AlternativeStrategies #HolisticHealth #GeneticInsights #PatientWellness